Antitumor Effect of Calcium-Mediated Destabilization of Epithelial Growth Factor Receptor on Non-Small Cell Lung...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Targeted therapies for non-small cell lung carcinoma (NSCLC) often face drug resistance.
• The epithelial growth factor receptor (EGFR) pathway is a key target in NSCLC treatment.
• Novel strategies are needed to overcome resistance to existing EGFR-targeted therapies.

Purpose of the Study:

• To investigate the antitumor effects of calcium-mediated protein degradation in NSCLC.
• To explore the potential of lactate calcium salt (LCS) as a therapeutic agent for NSCLC.
• To elucidate the mechanism by which LCS impacts EGFR signaling and downstream targets.

Main Methods:

• Utilized lactate calcium salt (LCS) for calcium supplementation in NSCLC cells.
• Measured protein levels (Src, α-tubulin, EGFR) using immunocytochemistry.
• Assessed downstream effects on c-Myc and cyclin D1 expression.
• Confirmed antitumor activity via colony formation assays and xenograft models.
• Employed calpeptin to validate calcium-mediated effects.

Main Results:

• LCS treatment reduced Src and α-tubulin expression in NSCLC cells.
• EGFR destabilization occurred due to proteolysis of Src and α-tubulin.
• Downstream signaling proteins c-Myc and cyclin D1 expression decreased.
• Significant inhibition of clonogenic ability and tumor growth was observed in vitro and in vivo.
• LCS demonstrated an antitumor effect via EGFR destabilization.

Conclusions:

• Proteolysis of EGFR-associated proteins (Src, α-tubulin) can induce EGFR destabilization and exert antitumor effects in NSCLC.
• Lactate calcium salt (LCS) represents a promising therapeutic candidate for overcoming chemoresistance in NSCLC.
• Targeting protein degradation pathways offers a novel approach to NSCLC treatment beyond direct EGFR inhibition.